NORADRENALINE KABI (Fresenius Kabi Australia Pty Ltd)
Product name
NORADRENALINE KABI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
123 (255 working days)
Active ingredients
noradrenaline (norepinephrine) acid tartrate monohydrate
Registration type
New generic medicine
Indication
For the restoration of blood pressure in certain acute hypotensive states (e.g., phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions).
As an adjunct in the treatment of cardiac arrest. To restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.